Jan van de Winkel – President & CEO, Genmab
Speaking exclusively to PharmaBoardroom, Jan van de Winkel highlights the tremendous progress that European biotech success story Genmab has made over the past six years, how its partnership model is…
Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company currently has one marketed antibody, Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications and daratumumab in clinical development for multiple myeloma and non-Hodgkin’s lymphoma, in addition to other clinical programs, and an innovative pre-clinical pipeline. Genmab’s technology base consists of validated and proprietary next generation antibody technologies – the DuoBody® platform for generation of bispecific antibodies, and the HexaBody® platform which creates effector function enhanced antibodies. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies.
Visiting Address
Yalelaan 60
3584 CM Utrecht
The Netherlands
Postal Address
P.O. Box 85199
3508 AD Utrecht
The Netherlands
Phone +31 30 2 123 123
Fax +31 30 2 123 110
Speaking exclusively to PharmaBoardroom, Jan van de Winkel highlights the tremendous progress that European biotech success story Genmab has made over the past six years, how its partnership model is…
The future of drug development is about interacting, sharing and collaborating. The President and CEO of Genmab, an international biotechnology company focusing on differentiated antibody therapeutics for the treatment of…
See our Cookie Privacy Policy Here
